S.Korea's Celltrion Healthcare jumps on robust Q2 earnings expectations
** S.Korea's Celltrion Healthcare 091990.KQ gains as much
as 15.6 pct to a near one-week high as analysts expect robust
earnings for the second quarter
** Celltrion Healthcare's earnings are likely to rebound in
June quarter on firm overseas sales, Sun Min-jeong, an analyst
at Hana Financial Investment said in a note
** The co's affiliate Celltrion 068270.KS also up as much
as 12.1 pct
** Broader market .KS11 down 0.1 pct as of 0613 GMT
((Reuters Messaging: dahee.kim@thomsonreuters.com))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap